Deletion of the WD40 Domain of LRRK2 in Zebrafish Causes Parkinsonism-Like Loss of Neurons and Locomotive Defect
Open Access
- 22 April 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 6 (4) , e1000914
Abstract
LRRK2 plays an important role in Parkinson's disease (PD), but its biological functions are largely unknown. Here, we cloned the homolog of human LRRK2, characterized its expression, and investigated its biological functions in zebrafish. The blockage of zebrafish LRRK2 (zLRRK2) protein by morpholinos caused embryonic lethality and severe developmental defects such as growth retardation and loss of neurons. In contrast, the deletion of the WD40 domain of zLRRK2 by morpholinos targeting splicing did not induce severe embryonic developmental defects; rather it caused Parkinsonism-like phenotypes, including loss of dopaminergic neurons in diencephalon and locomotion defects. These neurodegenerative and locomotion defects could be rescued by over-expressing zLRRK2 or hLRRK2 mRNA. The administration of L-dopa could also rescue the locomotion defects, but not the neurodegeneration. Taken together, our results demonstrate that zLRRK2 is an ortholog of hLRRK2 and that the deletion of WD40 domain of zLRRK2 provides a disease model for PD. Parkinson's disease (PD) is a degenerative disease of the brain (central nervous system) that often impairs motor skills, speech, and other functions. PD was long thought to be caused by environmental factors, but the discovery of several gene mutations in the patients (mostly with familial form of PD) clearly demonstrated the involvement of genetic factors in the development of PD. Among the identified genes, LRRK2 was discovered to be one of the most important genetic causes of PD. The biological function of LRRK2 was, however, largely unknown. In this study, we studied the function of LRRK2 in zebrafish by blocking the normal function of LRRK2. The zebrafish showed features of neurodegeneration and locomotion defects, similar to those of PD patients. The defects of the fish could be rescued by expressing the normal protein of LRRK2, and the locomotion defect could also be rescued by the administration of L-dopa that is commonly used for treating PD patients. We have therefore developed a zebrafish model for PD that can be used for understanding the mechanism underlying the development of PD and will be helpful for future screening of new drugs to treat PD.Keywords
This publication has 52 references indexed in Scilit:
- DCTN1 mutations in Perry syndromeNature Genetics, 2009
- The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular AutophosphorylationJournal of Biological Chemistry, 2008
- The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2Journal of Neuroscience, 2008
- A Drosophila model for LRRK2 -linked parkinsonismProceedings of the National Academy of Sciences, 2008
- Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neuronsMolecular Neurodegeneration, 2008
- The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubulesJournal of Neuroscience Research, 2008
- Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient miceProceedings of the National Academy of Sciences, 2007
- LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activityBiochemical Journal, 2007
- Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutantsJournal of Neurochemistry, 2007
- Electroporation-based methods for in vivo, whole mount and primary culture analysis of zebrafish brain developmentNeural Development, 2007